Biomarkers Market Research Reports
Biomarkers refer to genes, molecules or certain characteristics enabling to evaluate or measure pharmacologic response to therapeutic treatment, or various pathogenic or biological processes. Categorized by their utilization in different medical procedures, biomarkers facilitate decision-taking in early clinical drug development, thus helping to detect a patient’s health state. Oncology belongs within the major diseases where biomarkers are widely used.
Supported by novel product’s introductions, fresh market entrants, as well as M&As and other related activities, the world Biomarkers Market is evolving at a colossal tempo, set to be ultimately valued at just over EUR 26 billion by end-2018. Novel technologies exploited for biomarker discovery are the foremost contributors to the Biomarkers sector. North America heads the market as the most speedily growing geographic area. Major Biomarkers Market participants encompass, among others, Abbot Laboratories, Affymetrix, Agilent, Epigenomics, Celera, GE Healthcare, and DiagnoCure.
The research reports under this MarketPublishers’ Catalogue delve deep into the Biomarkers Market and its major submarkets – discovery technologies, services market, application market, and various indications. Covering various geographies, the research reports identify and examine the principal trends, opportunities, and the factors propelling or clogging the market growth. The competitive landscape with comprehensive profiles of numerous players in the global Biomarkers Industry, forecasts throwing light on the market’s future are provided in the research reports too.
... (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected ... technological and commercial possibilities. Eight ways Next-Generation Antibody Therapeutics Market 2013-2023 helps In particular, then, our investigation gives ...Feb, 2013 164 pages
... worlds leading healthcare companies during 2012 DESCRIPTION The Biomarker Partnering Yearbook 2013 report series provides comprehensive understanding and unprecedented ... , dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you ...Jan, 2013 200 pages
... to Optimize Therapeutic Outcomes Summary GBI Research’s new report, “Biomarkers in Drug Discovery - Integration in Early Stage Promotes Use of Companion Diagnostics to Optimize ... the unmet needs of the conventional drug discovery process. The drivers and barriers for the biomarkers market, along with the ...Nov, 2012 87 pages
... All Play Prominent Roles Summary GBI Research in its report “Endpoints - Clinical Trials in Respiratory Diseases - Pulmonary Function Tests, Biomarkers and Quality of ... are presented. This report presents detailed overview about the endpoint used in major marketed drugs and most promising molecules under ...Jun, 2012 194 pages
... growth will be seen. Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there ... (where there are products on the market) for personalized medicine technologies in the following categories: Cardiac Markers, immunoassays Cardiac Risk Markers ...Mar, 2011 430 pages
... price decline in 2011 onwards. This report details the endpoints in clinical trials for cardiovascular disorders, highlighting the five major cardiovascular ... as those related to the effectiveness of treatment as well as other factors. However, endpoint selection must take into account the need to obtain the ...Jan, 2012 152 pages
... and charts and two research interviews. Advantages of Next-Generation Antibody Therapies: Pipeline and Market 2011-2021 for your work ... and technological submarkets, seeing revenue prospects Assess companies in the antibodies industry, discovering activities and outlooks Receive a 2010 revenue breakdown ...Nov, 2011 185 pages
... biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic. The identification of therapy-indicating and prognostic ...Feb, 2013 103 pages
... and Others (miRNA Analysis and Others). The total market is also analyzed by the following Application Areas: Biomarker Discovery, Clinical Drug Development, and ... , Inc., Rules-Based Medicine, Inc., and Siemens Healthcare Diagnostics, Inc. Market data and analytics are derived from primary and secondary ...Aug, 2011 1305 pages
... Japan France, Germany, UK, Spain and Italy (EU5 countries) China India. Technological research in leading markets will drive worldwide growth in revenues for ... , 53 charts and two research interviews. Nine ways Biomarkers: Technological and Commercial Outlook 2012-2022 helps you In particular, our study ...Jul, 2012 162 pages